Followers | 47 |
Posts | 4611 |
Boards Moderated | 0 |
Alias Born | 07/26/2010 |
Tuesday, September 29, 2015 9:04:45 AM
My math shows 3.38 cash. Entered 1st position 1.89. Will add 2nd, 3rd, 4th positions on dip back to 1.50.
Recent VSTM News
- Form 8-K - Current report • Edgar (US Regulatory) • 01/23/2025 12:42:54 PM
- Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers • Business Wire • 01/23/2025 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/21/2025 09:30:28 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 01/21/2025 09:30:14 PM
- Verastem Oncology Names Matthew E. Ros as Chief Operating Officer • Business Wire • 01/15/2025 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/14/2025 09:30:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/14/2025 09:30:04 PM
- Verastem Oncology Exercises Option Early to License VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China • Business Wire • 01/14/2025 12:30:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/13/2025 10:03:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/13/2025 12:36:46 PM
- Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025 • Business Wire • 01/13/2025 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2025 09:30:16 PM
- Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 01/08/2025 12:30:00 PM
- Verastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination with Defactinib for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer • Business Wire • 12/30/2024 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/26/2024 09:30:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/20/2024 09:31:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/20/2024 09:30:10 PM
- Applied Therapeutics Appoints John H. Johnson as Executive Chairman • GlobeNewswire Inc. • 12/20/2024 12:00:00 PM
- Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer • Business Wire • 12/18/2024 12:30:00 PM
- Verastem Oncology to Present at the 7th Annual Evercore ISI HealthCONx Conference • Business Wire • 11/26/2024 12:00:00 PM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 11/14/2024 08:33:34 PM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 11/12/2024 02:35:38 PM
- Form SC 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 11/08/2024 07:17:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/07/2024 09:30:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/06/2024 09:22:57 PM
UC Asset Announces Plan of Secondary Public Offering via Reg A • UCASU • Jan 23, 2025 9:30 AM
Luke Plants Featured in U.S. Department of the Interior Report to Congress on Strategic Review of National Orphan Well Program • ZEFIF • Jan 21, 2025 10:51 AM
North Bay Resources Acquires 70% Interest in the Bishop Gold Mill, Inyo County, California • NBRI • Jan 21, 2025 9:26 AM
HealthLynked Unveils Release of ARi: A Revolutionary AI-Powered Healthcare Assistant • HLYK • Jan 21, 2025 8:00 AM
Good Gaming Inc. Announces ViaOne Services' Intent to Purchase Up to 10% of Its Common Shares in the Open Market • GMER • Jan 16, 2025 8:30 AM
Avant Technologies and Ainnova Begin Implementing and Testing Advanced AI Algorithms for Early Detection of Additional Diseases • AVAI • Jan 16, 2025 8:00 AM